Article
Reference
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
MASSA, Horace, et al.
Abstract
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN (R). The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN (R) in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.
MASSA, Horace, et al . Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review. The Journal of International Medical Research , 2019, vol. 47, no. 1, p. 31-43
PMID : 30556449
DOI : 10.1177/0300060518816884
Available at:
http://archive-ouverte.unige.ch/unige:142183
Disclaimer: layout of this document may differ from the published version.
1 / 1
Erratum
Erratum
Massa H, Nagar AM, Vergados A, Dadoukis P, Patra S and Panos GD. Intravitreal flu- ocinolone acetonide implant (ILUVIENVR) for diabetic macular oedema: a literature review.
Journal of International Medical Research 2018. 47(1): 31–43. DOI: 10.1177/
0300060518816884
We published this review article initially as part of the normal monthly issue but it was meant to have been published as a part of the“Special issue on Macular Diseases: Advances in Diagnostics and Therapeutics’’. We apologize for this error.
Journal of International Medical Research 2019, Vol. 47(2) 1099
!The Author(s) 2019 Article reuse guidelines:
sagepub.com/journals-permissions DOI: 10.1177/0300060519829969 journals.sagepub.com/home/imr
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
